[indiscernible] of Citi Global Healthcare Conference. My name is Geoff Meacham, I'm the senior biopharma analyst here. We're thrilled today to have Regeneron. And speaking on behalf of Regeneron, we ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

Thanks so much, everyone. It's funny. I had -- I was talking to an investor, and he -- it was his first time in London. He goes, it's not that crowded. And I think it's going to be okay, and I told ...

SARATOGA SPRINGS — Regeneron Pharmaceuticals, a global biotech company founded in New York City, is more than doubling its manufacturing capacity in the state, according to an announcement from the ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Morning, ...

Oct 8 (Reuters) - The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ (REGN.O), opens new tab immunotherapy, Libtayo, as an add-on treatment for skin cancer patients ...

Regeneron is racing to regulators after reporting a phase 3 win in an ultrarare disease. The biotech plans to file for FDA approval of garetosmab in fibrodysplasia ossificans progressiva (FOP) by the ...

Regeneron Pharmaceuticals said a late-stage study of its investigational drug garetosmab met its key goal in the ultra-rare genetic disorder fibrodysplasia ossificans progressiva, or FOP. Regeneron on ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday shared data from the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG).